Bausch, Salix Pilot Lifts Cirrhosis Care Adherence Across 4,251 Patients
Image
Laval – October 12, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.
The results will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, held October 9-14, 2026, in Nashville, Tennessee. The companies describe the findings as preliminary until presented and evaluated in peer-reviewed publications.